Long COVID and the Immune System: Viral Persistence, Autoimmunity, and Reactivation

One of the most important questions in Long COVID research is: why do symptoms persist long after the acute infection has resolved? Over the past four years, a growing body of evidence has converged on several interconnected immune mechanisms that appear to drive ongoing illness in a significant proportion of Long COVID patients.

Viral Persistence

Perhaps the most significant finding in Long COVID immunology is evidence that SARS-CoV-2 — or fragments of it — can persist in tissues long after the acute infection. Studies have detected viral RNA, spike protein, and nucleocapsid protein in the gut, lymph nodes, blood, and other tissues of Long COVID patients months to years after infection.

The implications are significant. If viral material is persisting in tissues, it could:

• Continuously stimulate the immune system, driving chronic inflammation
• Trigger ongoing autoimmune responses
• Reactivate latent herpesviruses by suppressing immune surveillance
• Directly damage tissues in which it persists

A 2023 study published in Nature found SARS-CoV-2 RNA in gut tissue of Long COVID patients up to 676 days after infection. Another study found spike protein in blood monocytes of Long COVID patients up to 15 months after infection.

This evidence is driving trials of extended antiviral therapy (Paxlovid, other antivirals) in Long COVID patients, based on the hypothesis that clearing residual virus may resolve symptoms.

Autoantibodies

Multiple studies have found elevated autoantibodies in Long COVID patients — antibodies that mistakenly target the body's own proteins. These include:

• Anti-ACE2 antibodies: Targeting the receptor SARS-CoV-2 uses to enter cells
• Anti-beta-adrenergic receptor antibodies: Targeting receptors that regulate heart rate and blood pressure — potentially explaining POTS and dysautonomia
• Anti-muscarinic receptor antibodies: Targeting receptors in the autonomic nervous system
• Antinuclear antibodies (ANA): Associated with autoimmune conditions
• Anti-phospholipid antibodies: Associated with clotting and cardiovascular complications

The presence of autoantibodies targeting autonomic receptors is particularly relevant for Long COVID patients with POTS or dysautonomia. It suggests that in some patients, dysautonomia may be autoimmune in nature — similar to autoimmune autonomic ganglionopathy — rather than purely structural.

Herpesvirus Reactivation

SARS-CoV-2 infection appears to reactivate latent herpesviruses in some patients, particularly Epstein-Barr virus (EBV). EBV infects approximately 95% of adults and remains latent in B cells for life. Under normal conditions, T cell surveillance keeps it suppressed. COVID-19 appears to disrupt this surveillance, allowing EBV to reactivate.

Studies have found:

• Elevated EBV viral loads in Long COVID patients compared to recovered controls
• EBV reactivation correlating with specific Long COVID symptoms (fatigue, cognitive dysfunction, lymphadenopathy)
• Possible benefit from antiviral therapy targeting EBV in some Long COVID patients

Other herpesviruses that may reactivate include HHV-6 (associated with cognitive symptoms and encephalitis) and cytomegalovirus (CMV).

T Cell Exhaustion and Dysregulation

Long COVID patients show evidence of T cell exhaustion — a state in which T cells that should be clearing infection become dysfunctional due to chronic antigen stimulation. Exhausted T cells express markers like PD-1, TIM-3, and LAG-3, and have reduced capacity to proliferate and kill infected cells.

This T cell exhaustion may explain both why viral persistence occurs (the immune system cannot fully clear the virus) and why Long COVID patients are more susceptible to reinfection and other infections.

Mast Cell Activation

There is growing evidence that mast cell activation plays a role in Long COVID, particularly in patients with symptoms overlapping with MCAS (flushing, hives, gastrointestinal symptoms, anaphylactoid reactions, and widespread inflammation). SARS-CoV-2 can directly activate mast cells through the ACE2 receptor and through IgE-mediated mechanisms.

For Long COVID patients with prominent MCAS-like symptoms, treatment with mast cell stabilizers (ketotifen, cromolyn sodium) and antihistamines (H1 and H2 blockers) has shown benefit in case series and small trials.

Microclotting and Endothelial Dysfunction

South African researcher Resia Pretorius has documented the presence of microclots — tiny fibrin amyloid microclots that are resistant to normal fibrinolysis — in the blood of Long COVID patients. These microclots may impair oxygen delivery to tissues, contributing to fatigue, brain fog, and exercise intolerance.

Treatments targeting microclotting, including triple anticoagulation therapy (aspirin, clopidogrel, and apixaban), have been used in some Long COVID clinics, though the evidence base is still developing and these approaches carry bleeding risks that require careful medical supervision.

What This Means for Treatment

The immune complexity of Long COVID means that treatment needs to be matched to the underlying mechanism driving a particular patient's symptoms. Key questions to explore with your doctor:

• Do you have evidence of viral persistence? (Gut symptoms, elevated inflammatory markers, response to antiviral trials)
• Do you have autoantibodies? (Testing for anti-adrenergic receptor antibodies is available at some research centers)
• Do you have evidence of herpesvirus reactivation? (EBV, HHV-6, CMV titers)
• Do you have MCAS features? (Serum tryptase, 24-hour urine prostaglandins, clinical symptom review)
• Do you have dysautonomia? (Tilt table test, NASA lean test)

The field is advancing rapidly. Immune profiling of Long COVID patients — identifying which mechanisms are active in a given individual — is likely to become the standard approach to treatment selection within the next few years.